Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 2Phase NA 1Phase 4 1Phase 3 1Phase 2/3 1

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 17Tumor-Agnostic 7Head & Neck 3Plasma cell 2Gastrointestinal 2Endocrine 2CNS 2Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Classical hematology 1Breast 1

Conditions

Thyroid Carcinoma, Anaplastic 2Neoplasms 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Everolimus 15Magnetic Resonance Spectroscopy 8lutetium Lu 177 dotatate 7pasireotide 5gallium Ga 68 dotatate 5Cisplatin 5Specimen Handling 4Positron Emission Tomography Computed Tomography 4Nivolumab 4Fluorodeoxyglucose F18 4Carboplatin 4Temozolomide 3Paclitaxel 3Octreotide 3Lutetium-177 3Ga(III)-DOTATOC 3Etoposide 3(177)Lu-DOTA-EB-TATE 3vandetanib 2pembrolizumab 2olaparib 2fluorodopa F 18 2dabrafenib 2copper dotatate CU-64 2cemiplimab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Trastuzumab 2Radiotherapy 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × dabrafenib × Endocrine × Clear all
NCT03975231 2026-04-08

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

City of Hope Medical Center

Phase 1 Recruiting
6 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT04418167 2025-09-03

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

JS InnoPharm, LLC

Phase 1 Suspended
71 enrolled
DermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡